LEMAITRE VASCULAR INC 8K

LeMaitre Vascular reported strong Q2 2026 results with raised guidance, declared a $0.25 quarterly dividend, and highlighted its ongoing $100 million share repurchase authorization and international growth initiatives.

LeMaitre Vascular, Inc. reported strong preliminary unaudited Q2 2026 financial results, including 10% year-over-year sales growth to $70.4 million, a 210 bps increase in gross margin to 72.1%, 26% growth in operating income to $20.4 million, and EPS of $0.74, while highlighting robust Artegraft and regional sales performance, providing Q3, Q4, and full-year 2026 guidance, and noting cash and marketable securities of approximately $376 million. The company also disclosed that its board approved a quarterly dividend of $0.25 per share payable on September 3, 2026 to shareholders of record on August 20, 2026, reaffirmed its previously authorized $100 million share repurchase program running through February 18, 2027, and announced details of an investor conference call and its continued use of certain non-GAAP financial measures and related reconciliations. Management emphasized the international expansion of Artegraft, ongoing salesforce and infrastructure investments including six warehouse expansions, and outlined key risk factors and forward-looking statement disclaimers tied to regulatory, operational, competitive, and financial uncertainties.

Filing Facts

CIK

1158895

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-332982

Alert Tier

7